ProShare Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $229K | Buy |
|
|||||
|
2024
Q3 | $327K | Buy |
|
|||||
|
2024
Q2 | $46.7K | Sell |
|
|||||
|
2024
Q1 | $108K | Buy |
|
|||||
|
2023
Q4 | $177K | Buy |
|
|||||
|
2023
Q3 | $190K | Buy |
|
|||||
|
2023
Q2 | $412K | Buy |
|
|||||
|
2023
Q1 | $491K | Sell |
|
|||||
|
2022
Q4 | $317K | Buy |
|
|||||
|
2022
Q3 | $379K | Buy |
|
|||||
|
2022
Q2 | $187K | Sell |
|
|||||
|
2022
Q1 | $400K | Sell |
|
|||||
|
2021
Q4 | $414K | Buy |
|
|||||
|
2021
Q3 | $678K | Sell |
|
|||||
|
2021
Q2 | $921K | Buy |
|
|||||
|
2021
Q1 | $746K | Buy |
|
|||||
|
2020
Q4 | $686K | Buy |
|
|||||
|
2020
Q3 | $461K | Buy |
|
|||||
|
2020
Q2 | $411K | Buy |
|
|||||
|
2020
Q1 | $150K | Sell |
|
|||||
|
2019
Q4 | $258K | Sell |
|
|||||
|
2019
Q3 | $220K | Buy |
|
|||||
|
2019
Q2 | $219K | Sell |
|
|||||
|
2019
Q1 | $301K | Buy |
|
|||||
|
2018
Q4 | $322K | Sell |
|
|||||
|
2018
Q3 | $474K | Sell |
|
|||||
|
2018
Q2 | $543K | Sell |
|
|||||
|
2018
Q1 | $625K | Buy |
|
|||||
|
2017
Q4 | $717K | Buy |
|
|||||
|
2017
Q3 | $521K | Buy |
|
|||||
|
2017
Q2 | $463K | Sell |
|
|||||
|
2017
Q1 | $374K | Sell |
|
|||||
|
2016
Q4 | $458K | Buy |
|
|||||
|
2016
Q3 | $324K | Sell |
|
|||||
|
2016
Q2 | $322K | Buy |
|
|||||
|
2016
Q1 | $402K | Sell |
|
|||||
|
2015
Q4 | $862K | Buy |
|
|||||
|
2015
Q3 | $588K | Sell |
|
|||||
|
2015
Q2 | $675K | Buy |
|
|||||
|
2015
Q1 | $431K | Buy |
|
|||||
|
2014
Q4 | $297K | Buy |
|